Evidence map›Paper›PMID 33060611›Full record

ArticleScientific reports2020

Immortalization of human hepatocytes from biliary atresia with CDK4

Manami Nishiwaki, Masashi Toyoda, Yoshie Oishi, Seiichi Ishida, Shin-Ichiro Horiuchi, Hatsune Makino-Itou, Tohru Kimura, Shin-Ichi Ohno, Takashi Ohkura, Shin Enosawa and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Immortalization Reversibility in the Context of Cell Therapy Biosafety.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Manami NishiwakiCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Masashi ToyodaCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Yoshie OishiCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Seiichi IshidaDivision of Pharmacology, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
Shin-Ichiro HoriuchiDivision of Pharmacology, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
Hatsune Makino-ItouCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Tohru KimuraLaboratory of Stem Cell Biology, Department of Biosciences, Kitasato University School of Science, Kanagawa, 252-0373, Japan.
Shin-Ichi OhnoCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Takashi OhkuraCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Shin EnosawaDivision for Advanced Medical Sciences, National Center for Child Health and Development, Tokyo, 157-8535, Japan.
Hidenori AkutsuCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Atsuko NakazawaCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.
Mureo KasaharaOrgan Transplantation Center, National Center for Child Health and Development, Tokyo, 157-8535, Japan.
Tohru KiyonoProject for Prevention of HPV-related Cancer, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-8577, Japan. tkiyono@east.ncc.go.jp.
Akihiro UmezawaCenter for Regenerative Medicine, National Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan. umezawa@1985.jukuin.keio.ac.jp.
National Center For Child Health and Development · JPNational Institute of Health Sciences · JPChiba Cancer Center · JPKitasato University · JPTokyo Metropolitan Institute of Gerontology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocytes are an important tool for in vitro toxicology testing. In addition to primary cultures, a limited number of immortalized cell lines have been developed. We here describe a new cell line, designated as HepaMN, which has been established from a liver associated with biliary atresia. Hepatocytes were isolated from a liver of 4-year-old girl with biliary atresia and immortalized by inoculation with CSII-CMV-TERT, CSII-CMV-Tet-Off, CSII-TRE-Tight-cyclin D1 and CSII-TRE-Tight-CDK4

Indexed as

Liver, ArtificialBiliary AtresiaCell Culture TechniquesCell LineChild, PreschoolCost-Benefit AnalysisCyclin D1Cyclin-Dependent Kinase 4Cytochrome P-450 CYP3AHepatocytesHumansKineticsLiverPhenotypePrincipal Component AnalysisRegenerative MedicineCCND1 protein, humanCDK4 protein, humanCyclin D1Cyclin-Dependent Kinase 4CYP3A4 protein, humanCytochrome P-450 CYP3ARifampinTelomeraseTERT protein, human

Identifiers

PMID33060611
PMCPMC7567112
OpenAlexW3093162706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.